IL278968B - Methods for treating atopic dermatitis by administering an il-4r antagonist - Google Patents

Methods for treating atopic dermatitis by administering an il-4r antagonist

Info

Publication number
IL278968B
IL278968B IL278968A IL27896820A IL278968B IL 278968 B IL278968 B IL 278968B IL 278968 A IL278968 A IL 278968A IL 27896820 A IL27896820 A IL 27896820A IL 278968 B IL278968 B IL 278968B
Authority
IL
Israel
Prior art keywords
antagonist
administering
methods
atopic dermatitis
treating atopic
Prior art date
Application number
IL278968A
Other languages
Hebrew (he)
Other versions
IL278968A (en
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/057898 external-priority patent/WO2014039461A1/en
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of IL278968A publication Critical patent/IL278968A/en
Publication of IL278968B publication Critical patent/IL278968B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
IL278968A 2012-09-07 2020-11-25 Methods for treating atopic dermatitis by administering an il-4r antagonist IL278968B (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261697972P 2012-09-07 2012-09-07
US201261738715P 2012-12-18 2012-12-18
US201361748588P 2013-01-03 2013-01-03
US201361764624P 2013-02-14 2013-02-14
US201361768229P 2013-02-22 2013-02-22
US201361770091P 2013-02-27 2013-02-27
US201361782420P 2013-03-14 2013-03-14
US201361816191P 2013-04-26 2013-04-26
FR1356759 2013-07-10
PCT/US2013/057898 WO2014039461A1 (en) 2012-09-07 2013-09-04 Methods for treating atopic dermatitis by administering an il-4r antagonist

Publications (2)

Publication Number Publication Date
IL278968A IL278968A (en) 2021-01-31
IL278968B true IL278968B (en) 2021-09-30

Family

ID=67734429

Family Applications (2)

Application Number Title Priority Date Filing Date
IL266941A IL266941A (en) 2012-09-07 2019-05-28 Methods for treating atopic dermatitis by administering an il-4r antagonist
IL278968A IL278968B (en) 2012-09-07 2020-11-25 Methods for treating atopic dermatitis by administering an il-4r antagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL266941A IL266941A (en) 2012-09-07 2019-05-28 Methods for treating atopic dermatitis by administering an il-4r antagonist

Country Status (8)

Country Link
JP (2) JP6901545B2 (en)
KR (1) KR102284244B1 (en)
HK (1) HK1251896A1 (en)
IL (2) IL266941A (en)
MX (1) MX2019002801A (en)
PT (1) PT2892927T (en)
SG (1) SG10201913822PA (en)
TW (1) TWI790457B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111514292B (en) * 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 Pharmaceutical use of anti-human interleukin 4 receptor alpha monoclonal antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
IL278968A (en) 2021-01-31
JP2021152042A (en) 2021-09-30
SG10201913822PA (en) 2020-03-30
KR102284244B1 (en) 2021-08-03
JP6901545B2 (en) 2021-07-14
JP2020059749A (en) 2020-04-16
IL266941A (en) 2019-07-31
KR20200069388A (en) 2020-06-16
PT2892927T (en) 2018-08-02
MX2019002801A (en) 2019-07-15
TWI790457B (en) 2023-01-21
HK1251896A1 (en) 2019-04-26
JP7256231B2 (en) 2023-04-11
TW202041536A (en) 2020-11-16

Similar Documents

Publication Publication Date Title
HRP20181227T1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
HRP20181963T1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK1222567A1 (en) Methods for treating nasal polyposis by administering an il-4r antagonist il-4r
ZA201906339B (en) Methods for treating pruritus
ZA201407459B (en) Method and apparatus for subscription sharing
EP2851378A4 (en) Method for producing oxymethylene copolymer
IL278968B (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
HK1209040A1 (en) Methods for treating vestibulotoxicity
IL271284A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EP2736517A4 (en) Pharmaceutical composition for treating atopic dermatitis
LT3010539T (en) Methods for treating nasal polyposis by administering an il-4r antagonist